0001193125-17-373765.txt : 20180124 0001193125-17-373765.hdr.sgml : 20180124 20171219172358 ACCESSION NUMBER: 0001193125-17-373765 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20171219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aptose Biosciences Inc. CENTRAL INDEX KEY: 0000882361 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 5955 AIRPORT ROAD, SUITE 228 STREET 2: . CITY: MISSISSAUGA STATE: A6 ZIP: L4V 1R9 BUSINESS PHONE: 647-479-9828 MAIL ADDRESS: STREET 1: 5955 AIRPORT ROAD, SUITE 228 CITY: MISSISSAUGA STATE: A6 ZIP: L4V 1R9 FORMER COMPANY: FORMER CONFORMED NAME: Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) DATE OF NAME CHANGE: 20140905 FORMER COMPANY: FORMER CONFORMED NAME: LORUS THERAPEUTICS INC DATE OF NAME CHANGE: 19990308 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC PHARMA INC DATE OF NAME CHANGE: 19970113 CORRESP 1 filename1.htm CORRESP

December 19, 2017

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

 

  Re: Aptose Biosciences Inc. (the “Company”)

Registration Statement on Form F-1 (File No. 333-221783)

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned respectfully requests that the effective date of the above-referenced registration statement be accelerated so that the same will become effective on December 21, 2017 at 5 PM EST, or soon thereafter as is practicable.

 

Very truly yours,
Aptose Biosciences Inc.
By:   /s/ William G. Rice
 

Name:

Title:

  

William G. Rice, Ph.D.

Chairman, President and Chief Executive Officer

cc: Daniel M. Miller (Dorsey & Whitney LLP)